| Supplementary cash flow information |
Supplementary cash flow information
Net change in other operating assets and liabilities
|
|
|
|
|
|
|
|
2018
$ |
|
|
2017
$ |
|
Accounts receivable and accrued interest receivable |
(108 |
) |
|
(23 |
) |
Prepaid expenses, deposits and other
|
(5,094 |
) |
|
2 |
|
Clinical trial contract deposits |
90 |
|
|
(448 |
) |
Accounts payable and accrued liabilities |
(888 |
) |
|
2,168 |
|
|
(6,000 |
) |
|
1,699 |
|
Interest received |
2,148 |
|
|
973 |
|
Cash flows from financing and investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short term investments |
|
|
Contingent consideration |
|
|
Derivative warrants December 28, 2016 |
|
|
Derivative warrants February 14, 2014 |
|
|
Common shares |
|
|
Warrants |
|
|
Contributed surplus |
|
Balance at
January 1, 2018 |
7,833 |
|
|
(3,792 |
) |
|
(8,948 |
) |
|
(2,845 |
) |
|
(499,200 |
) |
|
(906 |
) |
|
(18,360 |
) |
Cash flow - Purchases |
36,084 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Cash flow - Proceeds from short term investment |
(36,093 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Cash flow - Proceeds from exercise of warrants |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(3,071 |
) |
|
— |
|
|
— |
|
Cash flow - Proceeds from exercise of options |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(943 |
) |
|
— |
|
|
— |
|
Non-cash changes - Conversion to common shares |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(1,436 |
) |
|
906 |
|
|
530 |
|
Non-cash changes - Fair value adjustments |
— |
|
|
(236 |
) |
|
(6,527 |
) |
|
(3,427 |
) |
|
— |
|
|
— |
|
|
— |
|
Non-cash changes - Stock based compensation |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(6,860 |
) |
Non-cash changes - Opening adjustment on change in accounting policy
|
78 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Non-cash changes - Other
|
(13 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Balance at
December 31, 2018 |
7,889 |
|
|
(4,028 |
) |
|
(15,475 |
) |
|
(6,272 |
) |
|
(504,650 |
) |
|
— |
|
|
(24,690 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
January 1, 2017 |
— |
|
|
(5,440 |
) |
|
(7,405 |
) |
|
(1,733 |
) |
|
(299,815 |
) |
|
(971 |
) |
|
(17,017 |
) |
Cash flow - Purchases |
97,996 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Cash flow - Disposals |
(90,018 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Cash flow - Payments made |
— |
|
|
2,150 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Cash flow - Net proceeds from public offering |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(162,324 |
) |
|
— |
|
|
— |
|
Cash flow - Proceeds from exercise derivative warrants |
— |
|
|
— |
|
|
8,596 |
|
|
88 |
|
|
(8,684 |
) |
|
— |
|
|
— |
|
Cash flow - Proceeds from exercise warrants |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(232 |
) |
|
— |
|
|
— |
|
Cash flow - Proceeds from exercise options |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(3,912 |
) |
|
— |
|
|
— |
|
Non-cash changes - Conversion to Common Shares |
— |
|
|
— |
|
|
3,825 |
|
|
8,760 |
|
|
(21,334 |
) |
|
65 |
|
|
2,899 |
|
Non-cash changes - Fair value adjustments |
(78 |
) |
|
(502 |
) |
|
(17,808 |
) |
|
(10,973 |
) |
|
(2,899 |
) |
|
— |
|
|
— |
|
Non-cash changes - Stock Based Compensation |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(4,242 |
) |
Non-cash changes - Other
|
(67 |
) |
|
— |
|
|
3,844 |
|
|
1,013 |
|
|
— |
|
|
— |
|
|
— |
|
Balance at
December 31, 2017 |
7,833 |
|
|
(3,792 |
) |
|
(8,948 |
) |
|
(2,845 |
) |
|
(499,200 |
) |
|
(906 |
) |
|
(18,360 |
) |
|